Moreover, the changes in the alternative splicing of macroH2A1 have been reported in a variety of human cancers including breast [23], colorectal [24], lung [25, 26], testis, bladder, ovarian, endometrial and cervical cancers [26]. This evidence concerns the gene MACROH2A1 and cervical cancer.